Ravulizumab-CWVZ Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ravulizumab-CWVZ Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
60
Registered trials
112
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ravulizumab-CWVZ can convert its Monoclonal antibody profile and C5 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ravulizumab-CWVZ (query alias: ravulizumab) |
|---|---|
| Modality / target | Monoclonal antibody; C5; C5 inhibitors |
| Highest global status | Approved |
| Originator | Alexion Pharmaceuticals, Inc. |
| Active developers | Alexion Pharmaceuticals, Inc., AstraZeneca Global R&D (China) Co., Ltd., Alexion Europe SAS |
The MCP disease footprint includes Neuromyelitis Optica, Thrombotic Microangiopathies, AQP4-IgG positive Neuromyelitis optica spectrum disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07557420 | Phase 3 | Not yet recruiting | 21 | Adjudicated On-Trial Annualized Relapse Rate (ARR) |
| NCT07596784 | Phase 3 | Not yet recruiting | 20 | Change From Baseline in Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) Total Score at Week 26 |
| NCT07399730 | Not Applicable | Recruiting | 80 | Proportion of patient attaining Complete Thrombotic Microangiopathy (TMA) Response during observation (naïve) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 3, Single-arm, Open-label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Phase 3; n=18; evaluation: not stated. Reported fields: Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)(Least Squares Mean) = -81.3 percent change (95% Confidence Interval, -84.2 to -78.3); Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)(Least Squares Mean): P-Value = < 0.001; Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)(Least Squares Mean): P-Value = < 0.001
EFFICACY AND SAFETY OF RAVULIZUMAB VERSUS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: SYSTEMATIC REVIEW AND META-ANALYSIS
Not Applicable; n=1328; evaluation: Positive. Reported fields: -; -
REAL-WORLD BASELINE CHARACTERISTICS OF PATIENTS INITIATING RAVULIZUMAB FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: INSIGHTS FROM THE POLISH MULTICENTER OBSERVATIONAL STUDY (PNH RECORD)
Not Applicable; n=53; evaluation: Positive. Reported fields: Aplastic anemia = 38.5 % ; Aplastic anemia = 12.5 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ravulizumab-CWVZ addresses Neuromyelitis Optica, Thrombotic Microangiopathies, AQP4-IgG positive Neuromyelitis optica spectrum disorder. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-11-07 | Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million | Approved | Financial terms not disclosed |
| 2020-12-12 | AstraZeneca completed the acquisition of Alexion Pharmaceuticals, Inc. | Approved | US$39,000.0M stated total |
| 2017-12-07 | Alexion and Halozyme Enter License Agreement for ENHANZE Technology | Preclinical | US$40.0M upfront; US$640.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
